SII: Coronavirus vaccine will cost about `225/dose

‘100m doses for India’

New Delhi, Aug. 7: Serum Institute of India (SII) on Friday said it has entered into a new partnership with international vaccine alliance Gavi and Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of Covid-19 vaccines for India as well as other low and middleincome countries (LMICs).

“The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021,” SII said in a statement.

The company has set an affordable ceiling price of $3 (around `225) per dose, it added.

The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO prequalification, the statement said.

The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of USD 150 million to Gavi, which will be used to support the SII to manufacture the potential vaccine candidates and for future procurement of vaccines for lowand middle-income countries via Gavi’s COVAX Advance Market Commitment (AMC), the statement said.

“In an attempt to make our fight against COVID19 stronger and allembracing; SII has partnered with Gavi and the Bill & Melinda Gates Foundation to advance the manufacturing and delivery of up to 100 million doses of future COVID vaccines for India and low- and middleincome countries in 2021,” Serum Institute of India CEO Adar Poonawalla said.

THE BILL & MELINDA Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of $150 million to Gavi, which will be used to support the SII to manufacture the potential vaccine candidates